Sunlant Closes its Pre-IPO Round

Sunlant completed tens of millions of Pre-IPO rounds of financing, with investment from Jinhe Capital, Xiangcheng Financial Holdings, TEDA Hengding, and Lanhu Capital. This round of financing is mainly used for market expansion and promotion and increasing investment in new project research and development.

Sunlant bioengineering is the first company in the world to specialise in the application of CLIA, Multi-index parallel detection and full-automatic protein chip analysis technologies for systematic detection serious diseases.

Company has the lead position of full-automatic biochip detection platform, 2 research achievements of “863”program, one major industrial project in jiangsu province and more than 30 patents.

The output of the very first fully automated analytical system for the protein biochip has filled the gap in the multi-index detection field . The product has covered many AAA hospitals and health check-up institutions, breaking the long-term foreign product monopoly and technology blockade in the field of high technological detection.

Sunlant Bioengineering is providing the best clinical detection based on professional teams of research, produce, sales and aftersales.

The domestic chemiluminescence immunodiagnosis industry is in a period of rapid development, and the market is still dominated by imported brands represented by Roche and Abbott. Under the background of domestically substituted industries, Sanlian Bio has successfully launched the world's first fully automatic hard matrix microarray protein chip chemiluminescence analyzer, and developed supporting diagnostic products, which greatly reduces the testing costs of hospital patients and improves the primary medical system The detection efficiency of tumors and other diseases has increased rapidly in sales.

After the completion of this round of financing, on the one hand, the company will further increase the marketing of existing products and increase market coverage; on the other hand, it will further expand the product line based on the existing technology platform. At the same time, the company will also speed up the process of listing and use the capital market to achieve leapfrog development.